• Loading stock data...
PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Medical » Co-Diagnostics, Inc. Enters Into Lease for New, Upgraded Laboratory Facility

Co-Diagnostics, Inc. Enters Into Lease for New, Upgraded Laboratory Facility

Randy Whitney by Randy Whitney
April 26, 2019
in Medical, Technology
3 min read
28
0
Co-Diagnostics, Inc. Announces Joint Venture in India

Laboratory will meet CGMP Requirements of FDA; Will be BSL-2 to allow enhanced in-house verification and validation activities

SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today leasing a new and upgraded, CGMP-ready and Biological Safety Level 2 laboratory facility in Salt Lake City, Utah.

Co-Diagnostics CEO Dwight Egan remarked, “The upgraded facility is nearly perfectly appointed with the necessary amenities to immediately commence production operations. This site will help us to reduce our dependence on outside locations to complete robust validations of the Company’s products, and represents the next step in our growth as a world-class developer of molecular diagnostics. Our trained personnel will now have the capacity to manufacture high-quality products that meet the standards of the U.S. Food and Drug Administration, preparing the Company to seek future FDA approvals for sale domestically and export abroad.”

Mr. Egan continued, “This is another important milestone in the development of Co-Diagnostics as an emerging leader in the molecular diagnostics industry. We are bringing disruptive technology to the market that will dramatically improve test accuracy by reducing false positives via our CoPrimers™ technology, and facilitate multiplexing to test for a broad range of disease states in a patient in a single test which will cut costs to healthcare systems. We are excited with the opportunities ahead in the coming years.”

Biocontainment precautions are required for the safe handling of potentially dangerous biological agents in a laboratory environment. Biological Safety Levels (“BSL”) are determined by the Centers for Disease Control (“CDC”) as a way to categorize which specific controls are necessary for the containment of biological agents based on their risk, transmissibility, severity, etc. Containment levels range from the lowest, BSL-1, to BSL-4, with each level requiring increasingly strict precautions. The Company’s BSL-2 lab will allow trained staff members to conduct certain verification and validation activities on human samples in-house rather than sending investigational use test kits to other facilities. From the FDA website, a CGMP-certified facility refers the Current Good Manufacturing Practice regulations enforced by the FDA, and provides systems that assure proper design, monitoring, and control of manufacturing processes and facilities. The new facility will also house the corporate headquarters for the Company.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Tags: Co-DiagnosticsCODXFDAlaboratory
Randy Whitney

Randy Whitney

Randy is a marketing specialist with experience creating content for sports and real estate in New York City. He has written for Major League Baseball and Cut4 as well as contributed creatively to the growth and development of startups around the country.

Related Posts

Trump Retweets Richard Grenell’s Call to Ban Microsoft from Federal Contracts
Technology

Trump Retweets Richard Grenell’s Call to Ban Microsoft from Federal Contracts

June 12, 2020
155
Regeneron buy back shares from Sanofi
Medical

Regeneron to buy back $5 billion shares from Sanofi

May 25, 2020
132
Tiktok named its new CEO Kevin Mayer
Social Media

TikTok Named Kevin Mayer as its new CEO to Lead its U.S. Operations

May 19, 2020
153
Virgin Galactic
Technology

Richard Branson to Sell More Than a Fifth of Virgin Galactic Shares

May 12, 2020
116
Uber removes 3,700 employees or 14% of its global workforce
Technology

Uber Slashed 14% of its Global Workforce to Compensate COVID-19 Pandemic Losses

May 6, 2020
135
Airbnb Job Cuts COVID-19 Pandemic
Technology

Airbnb Cuts 1,900 Jobs to Compensate Losses

June 18, 2020
123
Currently Playing

Subscribe To Our Newsletter

Ad

PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2020 PublicWire.com

Navigate Site

  • About
  • #96576 (no title)
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • #370 (no title)

© Copyright 2020 PublicWire.com

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Public Wire Logo

Hello please subscribe to our newsletter to get up to date news weekly!

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.